Step 11 of 12: Organizational & People Readiness

The Internal Operating System That Determines Whether You Scale or Collapse Under Your Own Weight

Every step of this program so far has pointed outward: the market, the buyers, the partners, the hospitals.

This one points at the thing most likely to sink you. Which is the company you built to chase all of it.

Here's the uncomfortable version. Somewhere on LinkedIn right now, a founder is proudly listing themselves as head of sales, head of customer success, head of partnerships, and head of product. They think it reads as hustle. It reads as a single point of failure with a title.

This is Step 11 of the 12-Step MedTech Launch Recovery Program, and it's the one founders avoid the longest, because it's the one that implicates them personally. You can outsource a regulatory strategy. You cannot outsource the fact that your company is currently organized around one exhausted person's calendar.

Product, regulatory, GTM, clinical, partnerships. Founders will happily obsess over all of it. The org chart that has to execute it? That's a "we'll handle it later" item. And later is precisely when it breaks.

What Organizational Readiness Actually Means

Organizational readiness means your company is built to support the GTM strategy, hold quality, deliver consistent deployments, communicate without a game of telephone, scale without descending into chaos, and do all of it without setting your team on fire.

Hospitals notice more than you think.

They don't adopt technology from a company that looks disorganized, understaffed, or politically knotted internally.

And word travels fast in a small clinical world. Your reference calls, your KOLs, your VAC contacts all talk to each other. A clean internal engine produces a clean customer experience.

A chaotic one produces stalled accounts and a quiet reputation you'll never see forming.

There's a useful way to think about culture here, and it isn't the snacks, although my wife would say different.

Culture is how work actually gets done when you aren't in the room. It's what your team rewards, tolerates, and promotes. It isn't an HR project. It's strategy, and it's set almost entirely by how you behave.

Your leadership and communication style becomes the team norm.

Your risk appetite becomes the company's DNA.

Whatever you tolerate becomes the standard.

That's a lot of power to be wielding by accident.

How the Org Breaks Before the Market Does

• They hire too late. U.S. commercialization needs boots on the ground: sales, clinical support, deployment, customer success, field engineering. Founders keep trying to stretch a one-person team across a continent. The market is not impressed by your thrift.
  

• They hire reactively instead of strategically. Every hire becomes a response to a fire instead of a deliberate build. The problem is that reactive hiring also tends to happen before the fundamentals are there. Throwing headcount at a shaky foundation just gives you a bigger, more expensive version of the same problem.
  

• They never define who owns what. Ambiguity quietly destroys execution. Duplicated effort, dropped responsibilities, silent turf wars are expected from time to time...no one is perfect. Here's the rule that matters: if two people think they own something, nobody owns it. Write down the decision rights before the confusion writes them for you.
  

• They carry too much for too long. A founder personally running sales, customer success, partnerships, and strategy is not a flex. It's fragility with good PR. There is only one of you, and cognitive load is real. Every decision routed through your head is a decision the company can't make without you, which means the company can't actually move without you either.
  

• Their internal loops are broken. Product doesn't hear what sales hears. Clinical doesn't hear what support hears. Leadership gets a filtered, flattering version of reality. This is how a company drifts away from its own market without noticing, until a renewal call makes it very noticeable.
  

• They hire the wrong type of person for the role. Pedigree is not fit. A sales leader with a shiny logo on the resume who has only ever sold inside a big company, with a brand, a marketing engine, and a full deck of collateral behind them, is not automatically your person. Selling from zero is a different sport: no brand, no air cover, no team, and a product the buyer has never heard of. People who have only ever thrived inside the machine tend to freeze when the machine isn't there. Hire for the environment, not just the title.
  

• They lowball the right person and end up with the wrong one. Try to underpay real talent, or wave them off with a vague "we'll sort out equity later," and one of two things happens. The good ones walk and you settle for someone cheaper who can't do the job. Or the good one takes it, quietly resents it, and leaves the moment a fair offer shows up. Either way it comes back to bite you. So run the actual math. I'd rather hire the right person at three times the cost and shorten my runway to six months than hire the wrong person and stretch it to eighteen, because the wrong hire burns those eighteen months anyway, and then I'm rehiring with less cash, less time, and a team that's lost faith. Cheap hiring is the most expensive hiring there is.

The Core Components

• A hiring roadmap with actual timing. Build it proactively around commercial milestones, deployment volume, support load, and the product roadmap, not around whatever caught fire this week. Know your early U.S. roles cold: a commercial lead, clinical deployment specialists, customer success, field support, and a technical or integrations lead. And hire for quality without apology. And likely at the beginning you'll need someone who can wear multiple hats. A players hire A players; B players hire C players, and your top people will leave the moment they sense weak hires stacking up around them.
  

• Role clarity and decision rights. Every function needs defined responsibilities, measurable KPIs, clean handoffs, and clear authority to decide. As you add people, subtract the ambiguity. Headcount without clarity isn't a bigger team, it's a bigger mess.
  

• Founder and CEO alignment. This is the silent killer when it's off. Who owns U.S. strategy? Who owns GTM decisions? Who manages investors? Who sets roadmap priorities? If the top of the company is unclear on any of these, the rest of the org has no chance of being clear on anything.
  

• Communication as infrastructure. The loops between field and product, product and sales, clinical and customer success, leadership and everyone, are not a nice-to-have. They're load-bearing. When they break, product diverges from the market, issues repeat, and people burn out. Communication is the foundation to success internally.
  

• Learning to let go. At some point you have to give up the monopoly. On customer communication, on partnership ownership, on narrative control, on your reflex to inspect every initiative personally. The blunt goal, borrowed from every founder who has actually scaled, is to make the company run without you. That means succession thinking, real delegation, and publicly backing other leaders so the team stops treating you as the only adult in the room. Empowered teams compound. Micromanaged ones wait.
  

• Culture and psychological safety. People need permission to surface problems early, clarity on how much risk they're allowed to take, and support when a hospital is grinding them down. A team that fears mistakes stops taking the shots that scale you. And remember that a strong culture is not the same as a nice one. Strong sometimes means removing the toxic high performer so the rest of the team can breathe. Nice tolerates them until the good people quit.
  

Paying for the Risk

U.S. commercial talent is expensive, and it does not compare your offer to someone in Paris or Madrid. It compares to the company down the road. American sales and customer success people live on a base-plus-commission structure, an OTE, and they expect the variable half to be real and reachable. If your comp philosophy was built for a market where base salary is the whole story and commission is a rounding error, you will lose every good rep to the competitor who speaks their language.

The person leaving a stable job to join your unproven startup is taking a career risk, the same species of risk you took, just with less upside and the same mortgage.

If you can't or won't match the cash, you don't get to shrug. You owe them a real piece of what you're building. Cash or equity, but something that pays them for the bet.

So talk about equity like it's real, because to them it is. Equity usually means stock options: the right to buy shares later at today's price, the strike price. It vests over time, typically four years with a one-year cliff, so nobody walks in on day ninety with a fistful of ownership. It gets diluted at every raise. And it's a bet, not a bonus. Be honest about that, and honest about when it could ever turn into actual money.

Now the part that trips up European parents specifically. Options on a foreign private company are a headache for a U.S. employee: murky liquidity, ugly tax treatment, and a "trust me" valuation. If you're serious about hiring here, set up a real U.S. option pool under a proper plan, get a defensible 409A valuation, and put the mechanics in writing. If a true option pool is genuinely too heavy this early, phantom equity or stock appreciation rights can mimic the upside without issuing real shares, which at least lets people share in the win. Whatever route you choose, use a lawyer who structures these for a living. This is one of the few places where improvising costs you the exact people you were trying to recruit.

The founders who win this treat comp as a signal. Underpay and cling to every share, and you've told the market you don't believe in the upside either. Share it thoughtfully, and you attract people who behave like owners, because you made them into some.

How to Build It

1. Map your org for the next 24 months: roles, teams, owners, milestones.

2. Build a hiring roadmap tied to your GTM phases and hire to prevent fires, not to fight them.

3. Document responsibilities for every function so ownership is never a question.

4. Write down decision rights and prioritization rules, meaning who decides what, when, and how.

5. Put real communication cadences on the calendar, weekly to monthly to quarterly.

6. Align the leadership narrative so nobody hears mixed messages, ever.

7. Install cross-functional operating rhythms between sales, product, clinical, and support.

8. Push authority downward and let teams own outcomes.

9. Invest in developing your people so they grow as fast as the company does.

10. And build a culture that rewards transparency, where surfacing a problem early is treated as loyalty, not disloyalty.

The Bottom Line

Organizational and people readiness is the engine under everything else in this program. Your strategy, your GTM, your product, your clinical plan, none of it matters if the team isn't built to execute reliably when you're not personally in the room.

Founders who take organizational design seriously scale faster, break less, keep their best people, and earn trust from hospitals and investors who can smell instability from across a conference table.

Founders who ignore it drown in chaos that was entirely preventable.

And I'd genuinely rather help you build the internal engine now than get called in later to untangle it once burnout, resentment, and turf wars have already set like concrete.

Step 12 is the finale, and it closes the loop where plenty of founders quietly lose control: investor and board alignment. All the internal readiness in the world won't save you if the people funding you and the people governing you are rowing in a different direction than the team actually doing the work. So we'll pull the whole program together into a real launch, get your board and your investors aligned on what "ready" even means, and answer the only question that counts: are you truly ready to go, or just tired of waiting?

Check Your Readiness

Want to know how strong your internal engine really is?

👉 Take the U.S. Commercial Readiness Self-Assessment. Fast. Honest. Directional.

Curious about the other 11 steps to recovering your medtech business? Click here to learn more!

About the author

Robert Law is the founder of Metamorph MedTech, a go-to-market consulting practice built for medical device and healthcare AI companies that have cleared the FDA and now have to figure out what comes next. With a Kellogg MBA and hands-on experience across surgical robotics, implantable devices, and AI-powered platforms, Robert works in the space where great technology meets commercial reality: health economics, hospital sales strategy, VAC navigation, reimbursement positioning, and the kind of go-to-market infrastructure that turns pilots into revenue. He started Metamorph because too many good technologies were losing to bad commercial strategies, and that bothered him more than he could ignore. Learn more here.